Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments
暂无分享,去创建一个
M. Hall | K. Wennerberg | M. Hajdúch | M. Vähä-Koskela | Jing Tang | M. Fratelli | J. Saarela | K. Brimacombe | Ziaurrehman Tanoli | P. Pavlis | P. Gribbon | A. Zaliani | F. Bietrix | Evgeny Kulesskiy | Jehad Aldahdooh | Farhan Alam | Yinyin Wang | Umair Seemab | Min Shen | M. Hajdůch | Florence Bietrix
[1] S. Ciesek,et al. A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection , 2021, Scientific data.
[2] Krystal L. Matthews,et al. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo , 2020, Journal of Virology.
[3] Sam Michael,et al. An OpenData portal to share COVID-19 drug repurposing data in real time , 2020, bioRxiv.
[4] Benjamin J. Polacco,et al. A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.
[5] Bruno Coutard,et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication , 2020, Scientific Reports.
[6] Eva Forssell-Aronsson,et al. Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens , 2020, Scientific Reports.
[7] David Shum,et al. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs , 2020, Antimicrobial Agents and Chemotherapy.
[8] Seth M Steinberg,et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. , 2020, The New England journal of medicine.
[9] Krister Wennerberg,et al. Exploration of databases and methods supporting drug repurposing: a comprehensive survey , 2020, Briefings Bioinform..
[10] Xiangxiang Zeng,et al. Network-based prediction of drug-target interactions using an arbitrary-order proximity embedded deep forest , 2020, Bioinform..
[11] T. Aittokallio,et al. Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer , 2019, npj Systems Biology and Applications.
[12] Albert-László Barabási,et al. Network-based prediction of drug combinations , 2019, Nature Communications.
[13] Andrew R. Leach,et al. ChEMBL: towards direct deposition of bioassay data , 2018, Nucleic Acids Res..
[14] Balaguru Ravikumar,et al. Drug Target Commons 2.0: a community platform for systematic analysis of drug–target interaction profiles , 2018, Database J. Biol. Databases Curation.
[15] Juho Rousu,et al. Learning with multiple pairwise kernels for drug bioactivity prediction , 2018, Bioinform..
[16] Amos Bairoch,et al. The Cellosaurus, a Cell-Line Knowledge Resource. , 2018, Journal of biomolecular techniques : JBT.
[17] Elina Parri,et al. Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions , 2017, Cell chemical biology.
[18] Adam J Pawson,et al. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes , 2017, British journal of pharmacology.
[19] Juho Rousu,et al. Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors , 2017, PLoS Comput. Biol..
[20] S. Garattini,et al. Network-guided modeling allows tumor-type independent prediction of sensitivity to all-trans-retinoic acid , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] George Papadatos,et al. The ChEMBL database in 2017 , 2016, Nucleic Acids Res..
[22] Emanuel J. V. Gonçalves,et al. A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.
[23] Scott E. Martin,et al. Reproducible pharmacogenomic profiling of cancer cell line panels , 2016, Nature.
[24] Deng Pan,et al. DGIdb 2.0: mining clinically relevant drug–gene interactions , 2015, Nucleic Acids Res..
[25] Joshua A. Bittker,et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.
[26] Michael K. Gilson,et al. BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology , 2015, Nucleic Acids Res..
[27] Robert Clarke,et al. Enhancing reproducibility in cancer drug screening: how do we move forward? , 2014, Cancer research.
[28] Joshua A. Bittker,et al. Evolving BioAssay Ontology (BAO): modularization, integration and applications , 2014, J. Biomed. Semant..
[29] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[30] Paul Workman,et al. Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? , 2012, Clinical Cancer Research.
[31] Peter Murray-Rust,et al. Minimum information about a bioactive entity (MIABE) , 2011, Nature Reviews Drug Discovery.
[32] Nigel W. Hardy,et al. Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project , 2008, Nature Biotechnology.
[33] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[34] Krister Wennerberg,et al. Methods for High-Throughput Drug Combination Screening and Synergy Scoring , 2016, bioRxiv.